FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

Fibrinogen-like protein 2 (FGL2) mediates immune suppression in glioblastoma (GBM). Here, the authors show that FGL-2 expressed by GBM cancer cells acts by suppressing the differentiation of CD103+ DC cells required to activate the anti-tumor CD8+ T cell response via blocking GM-CSF signalling at NF...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jun Yan, Qingnan Zhao, Konrad Gabrusiewicz, Ling-Yuan Kong, Xueqing Xia, Jian Wang, Martina Ott, Jingda Xu, R. Eric Davis, Longfei Huo, Ganesh Rao, Shao-Cong Sun, Stephanie S. Watowich, Amy B. Heimberger, Shulin Li
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/985213d99a3d4bd49592495ca3e98840
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:985213d99a3d4bd49592495ca3e98840
record_format	dspace
spelling	oai:doaj.org-article:985213d99a3d4bd49592495ca3e988402021-12-02T15:36:06ZFGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation10.1038/s41467-018-08271-x2041-1723https://doaj.org/article/985213d99a3d4bd49592495ca3e988402019-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-08271-xhttps://doaj.org/toc/2041-1723Fibrinogen-like protein 2 (FGL2) mediates immune suppression in glioblastoma (GBM). Here, the authors show that FGL-2 expressed by GBM cancer cells acts by suppressing the differentiation of CD103+ DC cells required to activate the anti-tumor CD8+ T cell response via blocking GM-CSF signalling at NFKB, STAT1/5 and p38 level.Jun YanQingnan ZhaoKonrad GabrusiewiczLing-Yuan KongXueqing XiaJian WangMartina OttJingda XuR. Eric DavisLongfei HuoGanesh RaoShao-Cong SunStephanie S. WatowichAmy B. HeimbergerShulin LiNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Jun Yan Qingnan Zhao Konrad Gabrusiewicz Ling-Yuan Kong Xueqing Xia Jian Wang Martina Ott Jingda Xu R. Eric Davis Longfei Huo Ganesh Rao Shao-Cong Sun Stephanie S. Watowich Amy B. Heimberger Shulin Li FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
description	Fibrinogen-like protein 2 (FGL2) mediates immune suppression in glioblastoma (GBM). Here, the authors show that FGL-2 expressed by GBM cancer cells acts by suppressing the differentiation of CD103+ DC cells required to activate the anti-tumor CD8+ T cell response via blocking GM-CSF signalling at NFKB, STAT1/5 and p38 level.
format	article
author	Jun Yan Qingnan Zhao Konrad Gabrusiewicz Ling-Yuan Kong Xueqing Xia Jian Wang Martina Ott Jingda Xu R. Eric Davis Longfei Huo Ganesh Rao Shao-Cong Sun Stephanie S. Watowich Amy B. Heimberger Shulin Li
author_facet	Jun Yan Qingnan Zhao Konrad Gabrusiewicz Ling-Yuan Kong Xueqing Xia Jian Wang Martina Ott Jingda Xu R. Eric Davis Longfei Huo Ganesh Rao Shao-Cong Sun Stephanie S. Watowich Amy B. Heimberger Shulin Li
author_sort	Jun Yan
title	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
title_short	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
title_full	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
title_fullStr	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
title_full_unstemmed	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
title_sort	fgl2 promotes tumor progression in the cns by suppressing cd103+ dendritic cell differentiation
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/985213d99a3d4bd49592495ca3e98840
work_keys_str_mv	AT junyan fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT qingnanzhao fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT konradgabrusiewicz fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT lingyuankong fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT xueqingxia fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT jianwang fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT martinaott fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT jingdaxu fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT rericdavis fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT longfeihuo fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT ganeshrao fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT shaocongsun fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT stephanieswatowich fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT amybheimberger fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation AT shulinli fgl2promotestumorprogressioninthecnsbysuppressingcd103dendriticcelldifferentiation
_version_	1718386369260158976

FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

Ejemplares similares